Open-Label Study to Investigate the Humoral and Cellular Immune Response to Two Doses of VAX102 Influenza Vaccine in Healthy Adults

Trial Profile

Open-Label Study to Investigate the Humoral and Cellular Immune Response to Two Doses of VAX102 Influenza Vaccine in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs VAX 102 (Primary) ; VAX 102 (Primary)
  • Indications Influenza A virus infections
  • Focus Pharmacodynamics
  • Sponsors VaxInnate
  • Most Recent Events

    • 06 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top